DE60237613D1 - Neue pgc-1-isoformen und deren verwendungen - Google Patents

Neue pgc-1-isoformen und deren verwendungen

Info

Publication number
DE60237613D1
DE60237613D1 DE60237613T DE60237613T DE60237613D1 DE 60237613 D1 DE60237613 D1 DE 60237613D1 DE 60237613 T DE60237613 T DE 60237613T DE 60237613 T DE60237613 T DE 60237613T DE 60237613 D1 DE60237613 D1 DE 60237613D1
Authority
DE
Germany
Prior art keywords
pgc
nucleic acid
acid molecules
expression vectors
isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237613T
Other languages
English (en)
Inventor
Bruce M Spiegelman
Guillaume Adelmant
Pere Puigserver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE60237613D1 publication Critical patent/DE60237613D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE60237613T 2001-07-05 2002-07-03 Neue pgc-1-isoformen und deren verwendungen Expired - Lifetime DE60237613D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30346801P 2001-07-05 2001-07-05
PCT/US2002/021337 WO2003004613A2 (en) 2001-07-05 2002-07-03 Novel pgc-1 isoforms and uses therefor

Publications (1)

Publication Number Publication Date
DE60237613D1 true DE60237613D1 (de) 2010-10-21

Family

ID=23172241

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237613T Expired - Lifetime DE60237613D1 (de) 2001-07-05 2002-07-03 Neue pgc-1-isoformen und deren verwendungen

Country Status (8)

Country Link
US (2) US7250283B2 (de)
EP (1) EP1412374B1 (de)
JP (1) JP4495961B2 (de)
AT (1) ATE480620T1 (de)
AU (1) AU2002320301A1 (de)
CA (1) CA2451395C (de)
DE (1) DE60237613D1 (de)
WO (1) WO2003004613A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491547A1 (en) * 2002-02-13 2003-08-21 Dana-Farber Cancer Institute, Inc. Methods and composition for modulating type i muscle formation using pgc-1.alpha.-
JPWO2005093068A1 (ja) * 2004-03-29 2008-02-14 大日本住友製薬株式会社 新規タンパク質及びプロモーター
WO2006014529A1 (en) * 2004-07-07 2006-02-09 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating obesity
US7989179B2 (en) 2005-06-28 2011-08-02 Daiichi Sankyo Company, Limited LXR ligand testing method
US8858990B2 (en) 2009-09-17 2014-10-14 The Ohio State University Capsule of thermogenic cells for treating a metabolic disease
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426411B1 (en) * 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
JP4495787B2 (ja) 1997-05-30 2010-07-07 ダナ−ファーバー キャンサー インスティテュート インク． ＰＧＣ−１、新規な褐色脂肪ＰＰＡＲ▲下γ▼コアクチベーター
AU1763201A (en) * 1999-11-10 2001-06-06 Mitokor Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery

Also Published As

Publication number Publication date
EP1412374A4 (de) 2005-07-20
ATE480620T1 (de) 2010-09-15
WO2003004613A2 (en) 2003-01-16
US20040254362A1 (en) 2004-12-16
US7250283B2 (en) 2007-07-31
CA2451395A1 (en) 2003-01-16
EP1412374A2 (de) 2004-04-28
JP2004533842A (ja) 2004-11-11
JP4495961B2 (ja) 2010-07-07
EP1412374B1 (de) 2010-09-08
WO2003004613A3 (en) 2003-11-20
US20090098569A1 (en) 2009-04-16
AU2002320301A1 (en) 2003-01-21
CA2451395C (en) 2015-11-24

Similar Documents

Publication Publication Date Title
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
WO2003042362A8 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
ATE480620T1 (de) Neue pgc-1-isoformen und deren verwendungen
WO2001087978A3 (en) Human abc transporter and its use
WO2002103015A3 (en) Abca10 transporter
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
WO2002016591A3 (en) Human transporter family members and uses thereof
ATE433489T1 (de) 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen
WO2001014414A3 (en) Human abc2 transporter and uses thereof
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
DE60237236D1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
DE60136832D1 (de) Atcr-1, eine humane acyltransferase und verwendungen davon
DE60234047D1 (de) 15603, ein mitglied der humanen ionenkanal-familie
WO2003035840A3 (en) 69583 and 85924, novel human protein kinase family members and uses therefor
WO2002010401A3 (en) 18431 and 32374, human protein kinase family members and uses therefor
WO2002070690A3 (en) Abca5 transporter and uses thereof
DE60120974D1 (de) Proteinkinase-molekül 14911 und dessen anwendungen
WO2002070692A3 (en) Abca9 transporter and uses thereof
WO2002076174A3 (en) Fbh58295fl, a novel human amino acid transporter and uses thereof
WO2002070693A3 (en) Novel abca6 transporter and uses thereof
WO2002002602A3 (en) Slgp protein and nucleic acid molecules and uses therefor
WO2003025200A3 (en) Methods of using 22417, a novel human aminoprotease family member